Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-021-06781-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Lancet Oncol
January 2025
Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Veterans Affairs Center for Clinical Management Research, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology and Lung Precision Oncology Program, University of Michigan Division of Hematology/Oncology, Rogel Cancer Center, Institute for Health Policy and Innovation, and Center for Global Health Equity, Ann Arbor, MI, USA.
Oral and maxillofacial surgery (OMFS) 'controlled' second-degree places in the UK - there are sufficient numbers (with high application ratios) to meet current and future OMFS recruitment needs in the UK.
Br J Oral Maxillofac Surg
November 2024
Liverpool University Hospitals NHS Foundation Trust, United Kingdom. Electronic address:
In 2008 the Postgraduate Medical Education and Training Board (PMETB) Review of Oral and Maxillofacial Surgery (OMFS) recommended that OMFS specialty training should start with second-degree studies. This recommendation has not yet happened. Currently, no OMFS controlled places at medical/dental schools are directly linked to OMFS Specialty Training (ST) posts.
View Article and Find Full Text PDFReply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.
Eur Urol Oncol
October 2023
Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Reply to J.A. Garcia et al.
J Clin Oncol
August 2024
Susan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.
Pediatric neuromodulation for drug-resistant epilepsy: Survey of current practices, techniques, and outcomes across US epilepsy centers.
Epilepsia Open
April 2024
Department of Neurosurgery, Maria Fareri Children's Hospital, New York Medical Center, Valhalla, New York, USA.
Neuromodulation via Responsive Neurostimulation (RNS) or Deep Brain Stimulation (DBS) is an emerging treatment strategy for pediatric drug-resistant epilepsy (DRE). Knowledge gaps exist in patient selection, surgical technique, and perioperative care. Here, we use an expert survey to clarify practices.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!